Medicenna Unveils Key Immunotherapy Data at ASCO
Company Announcements

Medicenna Unveils Key Immunotherapy Data at ASCO

Medicenna Therapeutics (TSE:MDNA) has released an update.

Medicenna Therapeutics is set to present at the 2024 ASCO Annual Meeting, showcasing new data from their ABILITY-1 Study on MDNA11, an innovative immunotherapy for solid tumors, and comparing survival outcomes of bizaxofusp against a control arm for recurrent glioblastoma. Their presentations will highlight MDNA11’s potential in monotherapy and in combination with pembrolizumab, and bizaxofusp’s performance in Phase 2 trials for a lethal brain cancer.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Canadian Auto-Generated NewsdeskMedicenna to Present Innovative Cancer Data at Conferences
TipRanks Canadian Auto-Generated NewsdeskMedicenna Reports Promising Results with MDNA11
TipRanks Canadian Auto-Generated NewsdeskMedicenna Announces Breakthroughs in Cancer Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App